 2003 |
|
 December 8 |
Japanese medical-use patent issued for NF B decoy oligo
-Covering treatment and preventive drugs for ischemic diseases, organ transplantions and cancers - |
| December 2 |
AnGes MG receives green light from the Japanese Ministry of Health for its clinical trials for HGF genetic medicine
-Japan's first large-scale multi-centered double-blind clinical trials for genetic medicine underway - |
| October 14 |
AnGes MG and Hokkaido System Science Co., Ltd. establish corporate alliance
-Granting of manufacture and marketing rights for NFB decoy oligo reagent- |
| August 4 |
AnGes MG and Gene Design Inc. establish joint operations
- Granting manufacturing and marketing rights for a novel nucleic acid sequence - |
| July 28 |
Key Japanese patent issued covering HGF gene therapy |
| June 23 |
AnGes MG transfers part of HVJ-E operations to subsidiary |
| May 15 |
AnGes MG, Inc. and Goodman Co., Ltd. Execute Exclusive License |
| May 1 |
Clinical trials underway for HGF genetic medicine in the United States |
| March 24 |
Notification of joint genetic function analysis R&D |
| February 20 |
Notice on the Granting of Stock Options |
| February 20 |
Personnel Changes at AnGes MG |
| February 10 |
Key Personnel Change at AnGes MG |
| January 8 |
IND application approved for HGF genetic medicine
treating peripheral arterial diseases |
 |
|
